Back

Targeting the PCSK9 pathway: where do novel therapies fit in?

26 August 2022 (13:05 - 13:20)
Organised by:
Congress Presentation Part of: A decade of innovation, guidelines and paradigm shifts in LDL-C management (10th annual symposium) Lipid-Lowering Agents Open Access ESC Congress 2022

About the speaker

Photo
Associate Professor Ann Marie Navar

University of Texas Southwestern Medical Center, Dallas (United States of America)

4 More presentations in this session

Presentation thumbnail
Introduction: changing paradigms in LDL-c reduction.
Professor K. Ray (London, GB)
Slides Video
Presentation thumbnail
LDC-c: new insights into its role as causal risk factor and target for therapy
Professor B. Ference (Cambridge, GB)
Slides Video
Presentation thumbnail
Addressing the unmet needs in LDL-c lowering: what can we expect?
Professor J. Kastelein (Amsterdam, NL)
Slides Video
Presentation thumbnail
Discussion.
Professor K. Ray (London, GB)
Slides Video

Access the full session

Session thumbnail
A decade of innovation, guidelines and paradigm shifts in LDL-C management (10th annual symposium)
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 13:05 CET
You may be interested in
thumbnail
Congress Presentation
PCSK9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: a systematic review and meta-analysis
thumbnail
Congress Presentation
Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials
thumbnail
Congress Presentation
PCSK9 inhibition: new insights

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources